Anaveon

Bottmingen, Switzerland

Anaveon is a developing IL-2 complexes which selectively promote effector T cell functions.

$119.7M raised

Dec 2021

Series B

Top Investors

30,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Anaveon raised?

Anaveon has raised $119.7M in total funding. The most recent round was Series B. The last funding was announced in December 2021.

Who are Anaveon's investors?

Anaveon's investors include Forbion Capital Partners, Pfizer Venture Investments, Cowen Healthcare Investments, Pontifax, Novartis Venture Fund.

Where is Anaveon headquartered?

Anaveon is headquartered in Bottmingen, Switzerland.

What does Anaveon do?

Anaveon is a developing IL-2 complexes which selectively promote effector T cell functions.

What stage is Anaveon at?

Anaveon is at the Series B stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated December 16, 2021.

MLA

"Anaveon — Funding & Investors." VCBacked, December 16, 2021, https://www.vcbacked.co/company/anaveon. Accessed July 2, 2026.

APA

VCBacked. (2021). Anaveon — Funding & Investors. Retrieved July 2, 2026, from https://www.vcbacked.co/company/anaveon

Wikipedia (cite web)

{{cite web |title=Anaveon — Funding & Investors |url=https://www.vcbacked.co/company/anaveon |website=VCBacked |access-date=July 2, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated December 16, 2021.